



Jamieson
WELLNESS™

QUARTERLY UPDATE

Q1 2026



Forward Looking Information



This presentation contains “forward-looking information” within the meaning of applicable securities laws. Forward looking information may relate to our future outlook and anticipated events or results and may include information regarding our financial position, business strategy, growth strategy, budgets, operations, financial results, taxes, dividend policy, plans, intentions, beliefs, and objectives of our Company. Particularly, information regarding our expectations of future results, performance, achievements, prospects or opportunities is forward looking information. In some cases, forward looking information can be identified by the use of forward looking terminology such as “plans”, “targets”, “expects”, “does not expect”, “is expected”, “an opportunity exists”, “budget”, “scheduled”, “estimates”, “outlook”, “forecasts”, “projection”, “prospects”, “strategy”, “intends”, “anticipates”, “does not anticipate”, “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might”, “will”, “will be taken”, “occur” or “be achieved”. In addition, any statements that refer to expectations, intentions, projections or other characterizations of future events or circumstances contain forward looking information. Statements containing forward looking information are not historical facts but instead represent management’s expectations, estimates and projections regarding future events or circumstances. In addition, our assessments of, and targets for, annual revenue, Adjusted EBITDA, Adjusted diluted earnings per share and certain other measures are considered forward looking information. See the section titled “Outlook” in our most recently filed MD&A for additional information concerning our strategies, assumptions and market outlook related to these assessments.

The forward-looking information contained in this presentation is based on management’s opinions, estimates and assumptions in light of its experience and perception of historical trends, current conditions and expected future developments, as well as other factors that we believe to be appropriate and reasonable in the circumstances. Despite a careful process to prepare and review the forward-looking information, there can be no assurance that the underlying opinions, estimates and assumptions will prove to be correct. Certain assumptions in respect of the ability to pursue further strategic acquisitions; our ability to source raw materials and other inputs from our suppliers; our ability to continue to innovate product offerings that resonate with our target customer base; our ability to retain key management and personnel; our ability to continue to expand our international presence and grow our brand internationally; our ability to obtain and maintain existing financing on acceptable terms; currency exchange and interest rates; the impact of competition; changes to trends in our industry or global economic factors; and changes to laws, rules, regulations and global standards are material factors made in preparing the forward looking information and management’s expectations contained in this presentation.

The forward-looking information contained in this presentation represents management’s expectations as of the date of this presentation and is subject to change after such date. However, we disclaim any intention or obligation or undertaking to update or revise any forward-looking information whether as a result of new information, future events or otherwise, except as required under applicable securities laws in Canada.

Forward-looking information is necessarily based on a number of opinions, estimates and assumptions that management considered appropriate and reasonable as of the date such statements are made, is subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward-looking information, including but not limited to those described under the heading “Risk Factors” in our annual MD&A for the fiscal year ended December 31, 2025 and in our most recent annual information form.

We caution that the list of risk factors and uncertainties under the heading “Risk Factors” is not exhaustive and other factors could also adversely affect our results. Readers are urged to consider the risks, uncertainties and assumptions carefully in evaluating the forward-looking information and are cautioned not to place undue reliance on such information.

NON-IFRS FINANCIAL MEASURES

This presentation may make reference to the following non IFRS financial measures: “EBITDA”, “Adjusted EBITDA”, “Adjusted net earnings”, “normalized gross profit”, “normalized SG&A”, “normalized earnings from operations”, “cash from operating activities before working capital considerations” and “net debt”, the following non-IFRS ratios: “Adjusted EBITDA margin”, “Adjusted diluted earnings per share”, “normalized gross profit margin”, “normalized operating margin”, and the following supplementary financial measures: “gross profit margin”, “operating margin” and “USD denominated revenue”, to provide supplemental measures of our operating performance and thus highlight trends in our core business that may not otherwise be apparent when relying solely on IFRS financial measures. Accordingly, these measures should not be considered in isolation nor as a substitute for analysis of our financial information reported under IFRS. For further details on these non-IFRS measures, non-IFRS ratios, and supplementary financial measures, including relevant definitions and certain reconciliations, see our most recently filed MD&A.

好品质 无微不至

加拿大百年品质 始于1922

健美生品牌大使董璇



维B缓释片 生物素 儿童叶黄素 磷虾油

First Quarter 2026 Highlights



- 1 Growth in Canada led by continued strength in the immunity, sleep and stress categories and supported by the made in Canada, quality-focused marketing campaign
- 2 Revenue growth in China driven by strong Women's Day promotional performance featuring Biotin and vitamins B and C
- 3 Acceleration in digital commerce and continued demand for hero products in key retailers led growth in the U.S.
- 4 Demand generating International campaigns in support of immunity, women's health and heart health combined with new product launches and expanded distribution drove growth in top markets



First Quarter 2026 Summary of Segment Results

- Revenue was **\$151.9 million**, an increase of **15.6%** or **\$20.5 million**



- Gross profit increased **\$12.8 million** to **\$66.6 million**; normalized gross profit margin increased by **220 bps**, mainly driven by higher volumes in China, the Company's highest gross margin business
- Adjusted EBITDA¹ increased by **\$2.8 million** to **\$21.1 million**, driven by higher gross profit and partially offset by SG&A due to performance marketing campaign investments

¹ This is a non-IFRS financial measure. See the "Non-IFRS and Other Financial Measures" section of this presentation for more information on each non-IFRS financial measure.



STRATEGIC PARTNERS

First Quarter 2026 Summary of Segment Results

- Revenue was **\$17.9 million**, an expected increase of **22.6%** or **\$3.3 million**, driven by customer ordering patterns and shipment of new business secured in Fiscal 2025
- Gross profit increased **72.0%** or **\$1.0 million** to **\$2.5 million**
- Gross profit margin¹ increased by **400 basis points**, driven mainly by favourable customer mix and higher plant utilization
- Adjusted EBITDA² increased by **72.3%** or **0.6 million** to **\$1.4 million**
Adjusted EBITDA margin³ increased by **220 basis points** mainly due to higher gross profit

¹ This is a supplementary financial measure. See the “Non-IFRS and Other Financial Measures” section of this presentation for more information on each supplementary financial measure.

² This is a non-IFRS financial measure. See the “Non-IFRS and Other Financial Measures” section of this presentation for more information on each non-IFRS financial measure.

³ This is a non-IFRS ratio. See the “Non-IFRS and Other Financial Measures” section of this presentation for more information on each non-IFRS ratio.





First Quarter 2026

Balance Sheet and Cash Flow

- As at March 31, 2026, the Company had approximately **\$93.7 million** in cash and available revolving and swingline facilities and net debt¹ of **\$406.3 million**
- The Company used **\$5.8 million** in cash from operations compared to **\$31.6 million** generated in Q1 2026
- Cash from operating activities before working capital considerations of **\$12.6 million** compared to **\$4.7 million** in Q1 2025
- Cash invested in working capital increased by **\$45.3 million** due to higher inventory levels to support the growth of the business and secure supply amidst tariff uncertainties, and the timing of accounts receivable
- During the period ended March 31, 2026, the Company purchased for cancellation 200,506 Common Shares under its NCIB program for an aggregate consideration of **\$6.9 million**

¹ This is a supplementary financial measure. See the "Non-IFRS and Other Financial Measures" section of this presentation for more information on each supplementary financial measure.

First Quarter 2026 Consolidated Results



METRIC	Q1 2026	Q1 2025	Growth Rate
Consolidated Revenue	\$169.8	\$146.0	16.3%
Canada	\$75.3	\$72.4	4.0%
U.S.	\$21.5	\$20.7	3.7%
China	\$43.3	\$28.5	51.9%
International	\$11.8	\$9.8	20.9%
Total Jamieson Brands Segment	\$151.9	\$131.4	15.6%
Strategic Partners Segment	\$17.9	\$14.6	22.6%
Consolidated Adjusted EBITDA ¹	\$22.4	\$19.1	17.6%
Consolidated Adjusted EBITDA Margin ²	13.2%	13.1%	10 bps
Adjusted diluted EPS	\$0.17	\$0.14	21.4%

¹ This is a supplementary financial measure. See the "Non-IFRS and Other Financial Measures" section of this presentation for more information on each supplementary financial measure.

² This is a non-IFRS ratio. See the "Non-IFRS and Other Financial Measures" section of this presentation for more information on each non-IFRS ratio.

Summary Consolidated Financial Information



(\$ in millions, except as otherwise noted)	Fiscal Year Ended					
	December 31,					
	2025	2024	2023	2022	2021	2020
Revenue	822.1	733.8	676.2	547.4	451.0	403.7
Cost of sales	483.7	458.2	442.6	349.0	288.6	258.9
Selling, general and administrative expenses	216.2	174.5	140.3	110.2	80.7	76.3
Share-based compensation	8.4	7.3	5.9	4.9	5.7	4.9
Acquisition related adjustments	(3.8)	(12.4)	(7.9)	--	--	--
Earnings from operations	117.5	106.3	95.3	83.2	76.0	63.6
Foreign exchange loss/(gain)	1.9	1.5	2.0	0.3	(0.1)	0.5
Interest expense and other financing costs	22.4	20.3	22.8	12.4	5.7	6.0
Accretion on preferred shares	3.4	8.7	4.8	--	--	--
Earnings before income taxes	89.8	75.8	65.7	70.5	70.5	57.0
Provision for income taxes	25.4	24.7	19.6	17.7	18.4	15.5
Net earnings	64.5	51.1	46.0	52.8	52.1	41.6
Revenue	822.1	733.8	676.2	547.4	451.0	403.7
Adjusted EBITDA	159.7	141.0	138.1	123.8	100.1	88.0
Adjusted EBITDA Margin	19.4%	19.2%	20.4%	22.6%	22.2%	21.8%
Adjusted Net Earnings	79.4	69.0	66.1	65.1	55.2	47.9
Adjusted Net Earnings Per Fully Diluted Share	1.85	1.61	1.55	1.55	1.32	1.16

Summary Consolidated Financial Information



	Three Months Ended March 31,		% Change
	2026	2025	
<i>(\$ in millions, except as otherwise noted)</i>			
Revenue	169.8	146.0	16.3%
Cost of sales	100.7	90.7	10.9%
Gross profit margin	40.7%	37.8%	2.9%
Selling, general and administrative expenses	52.5	49.7	6.0%
Share-based compensation	2.4	2.1	13.5%
Earnings from operations	14.2	3.5	299.4%
Foreign exchange loss	(1.2)	0.5	(344.2%)
Interest expense and other financing costs	5.1	4.8	3.2%
Accretion on preferred shares	-	2.3	(100.0%)
Income before income taxes	10.3	(4.1)	349.6%
Provision for/(recovery of) income taxes	0.7	(1.6)	144.9%
Net earnings	9.6	(2.5)	481.9%
Adjusted EBITDA	22.4	19.1	17.6%
Adjusted EBITDA Margin	13.2%	13.1%	0.1%
Adjusted Net Earnings	7.4	5.9	24.7%
Adjusted Earnings Per Share	0.17	0.14	21.4%

Reconciliation of net income to EBITDA, adjusted EBITDA and adjusted net income



(\$ in millions, except as otherwise noted)	Three Months Ended		Fiscal Year Ended				
	March 31,		December 31,				
	2026	2025	2025	2024	2023	2022	2021
Net earnings	9.6	(2.5)	64.5	51.1	46.0	52.8	52.1
Provision for income taxes	0.7	(1.6)	25.4	24.7	19.6	17.7	18.4
Interest expense and other financing costs	5.1	4.8	22.4	20.3	22.8	12.4	5.7
Accretion on preferred shares	--	2.3	3.4	8.7	4.8	--	--
Depreciation and amortization	5.0	4.8	19.7	18.5	20.3	17.2	14.3
EBITDA	20.4	7.8	135.3	123.3	113.6	100.2	90.4
Share-based compensation	2.3	2.1	8.4	7.3	5.9	4.9	5.7
Foreign exchange loss (gain)	(1.2)	0.5	1.9	1.5	2.0	0.3	(0.1)
Acquisition and divestiture related costs	--	--	--	1.2	8.4	12.9	--
Amortization of fair value adjustments	--	--	--	--	8.4	0.8	--
Labour relations costs	--	--	--	7.2	--	--	--
COVID-19 related costs	--	--	--	--	--	0.2	2.4
IT implementation and business integration	0.6	5.6	11.5	11.6	7.7	4.5	1.9
Acquisition related purchase consideration and post-closing adjustments	--	--	(3.8)	(12.4)	(7.9)	--	--
Donations	--	3.1	3.1	--	--	--	--
Due diligence, legal, and other	0.3	--	3.3	1.4	--	--	(0.1)
Adjusted EBITDA	22.4	19.1	159.7	141.0	138.1	123.8	100.1
Provision for income taxes	(0.7)	1.6	(25.4)	(24.7)	(19.6)	(17.7)	(18.4)
Interest expense and other financing costs	(5.1)	(4.9)	(22.4)	(20.3)	(22.8)	(12.4)	(5.7)
Depreciation and amortization	(5.0)	(4.8)	(19.7)	(18.5)	(20.3)	(17.2)	(14.3)
Share-based compensation	(2.3)	(2.0)	(7.9)	(6.8)	(5.5)	(6.3)	(5.5)
Tax deduction from vesting of certain share-based awards	(2.0)	(0.7)	(0.7)	--	(1.0)	--	--
Tax effect of normalization adjustments	0.1	(2.4)	(4.2)	(1.7)	(2.8)	(4.9)	(1.1)
Adjusted net earnings	7.4	5.9	79.4	69.0	66.1	65.1	55.2
Adjusted EBITDA	22.4	19.1	159.7	141.0	138.1	123.8	100.1
Less capital expenditures	2.6	2.0	12.7	9.2	6.1	13.9	21.5
Simple free cash flow	19.8	17.1	147.0	131.8	132.0	109.8	78.6
Simple free cash flow conversion	88%	90%	92%	93%	96%	89%	79%

Financial Performance: 2026 Guidance



METRIC	2025	2026 TARGET RANGE	GROWTH RATE
Total Revenue	\$822.1	\$895.0 - \$935.0	9.0% - 13.7%
Jamieson Brands Segment			
• Canada	\$372.3	\$387.0 - \$395.0	4.0% - 6.0%
• U.S.	\$147.5	\$162.0 - \$170.0	14.0% - 19.0%**
• China	\$142.7	\$178.0 - \$193.0	25.0% - 35.0%
• International	\$64.1	\$67.0 - \$71.0	10.0% - 15.0%**
Total Jamieson Brands Segment	\$726.6	\$795.0 - \$825.0	9.4% - 13.6%
Strategic Partners Segment	\$95.5	\$100.0 - \$110.0	5.0% - 15.0%
Adj. EBITDA ¹	\$159.7	\$174.0 - \$181.0	9.0% - 13.4%
Adj. EBITDA Margin ²	19.4%	Approximately 19.4%	0 bps
Adj. Diluted Earnings per Share	\$1.85	\$2.08 - \$2.21	12.5% - 19.5%

This outlook reflects the following assumptions:

- Normalized SG&A are expected to increase 10% to 16%
- A fully diluted share count of approximately 42.5 million shares
- The Company's 2026 guidance reflects the current prevailing trade environment between the United States, Canada and other countries. To date, tariffs have not had a material impact on the Company's overall financial performance, as these costs have been mitigated through the Company's flexible supply chain and operating efficiencies. The Company recognizes that the trade environment is constantly changing, and actual results may be impacted by future changes in global trade policies.

*Company guidance updated on May 7, 2026.
 *All \$ figures in CAD millions
 ** Growth rates % in USD/local currency, with a USD conversion at 1.35

¹ This is a supplementary financial measure. See the "Non-IFRS and Other Financial Measures" section of this presentation for more information on each supplementary financial measure.

² This is a non-IFRS ratio. See the "Non-IFRS and Other Financial Measures" section of this presentation for more information on each non-IFRS ratio.



INVESTOR RELATIONS CONTACT:

Ruth Winker
rwinker@jamiesonlabs.com

 [linkedin.com/company/jamiesonwellness](https://www.linkedin.com/company/jamiesonwellness)

 twitter.com/JWEL_Canada

